Ono Pharmaceutical Co., Ltd.

Sho Kouyama

Takashi Kondo

Taihei Nishiyama

Motoyuki Tanaka

Atsushi Hiramatsu

Tomoyuki Koda

Yasuo Hirooka

Ryo Suzuki

Gareth Neil Brace

Shingo Nakatani

Akira Imagawa

Steve Courtney

Chris Yarnold

Osamu Ichihara

Stuart Flanagan

Elise Gadouleau

John Barker

Anthony Richardson

Barker John

Gareth Brace

A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.

Dihydroindolizinone derivative

The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases. 

Pyrimidinone and its derivatives inhibiting factor XIa

Pyridinone and pyrimidinone derivatives as factor Xia

Growing community of inventors

Osaka, Japan

Sho Kouyama